Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;27(5):790-794.
doi: 10.1177/1352458520946017. Epub 2020 Aug 4.

Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab

Chiara Rosa Mancinelli  1 , Cristina Scarpazza  2 , Cinzia Cordioli  1 , Nicola De Rossi  1 , Sarah Rasia  1 , Maria Vittoria Turrini  1 , Ruggero Capra  1
Affiliations

Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab

Chiara Rosa Mancinelli et al. Mult Scler. 2021 Apr.

Abstract

Discontinuation of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) at risk of progressive multifocal leukoencephalopathy (PML) is associated with disease reactivation. Forty-two RRMS patients, who switched from an extended interval dose (EID) of natalizumab to ocrelizumab, underwent magnetic resonance imaging (MRI) and clinical monitoring during washout and after ocrelizumab starting. During the first 3 months, disease reactivation was observed in five (12%) patients; 6 months after ocrelizumab starting, no further relapses were recorded, and Expanded Disability Status Scale (EDSS) remained stable in 38 (90%) patients. In conclusion, ocrelizumab could be considered a choice to mitigate the risk of disease reactivation in patients previously treated with natalizumab-EID.

Keywords: Natalizumab; extend interval dosing (EID); ocrelizumab; switching.

PubMed Disclaimer

MeSH terms

LinkOut - more resources